BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Market News

Moderna Brings Back Operations Chief as Oncology Push Demands Manufacturing Scale

Moe Alsumidaie by Moe Alsumidaie
October 1, 2026
in Market News
0
83
SHARES
1.4k
VIEWS
Share on XShare on LinkedInShare on Facebook

Moderna has created a Chief Operating Officer role and named Juan Andres to fill it, effective October 5, 2026. Andres previously led Moderna’s manufacturing expansion through the COVID-19 vaccine surge before retiring in 2023. The move signals that the company is preparing for the operational demands of launching intismeran autogene, its jointly developed cancer immunotherapy with Merck, following positive Phase 3 results, while managing an expanded infectious disease franchise that now includes five approved vaccines.

The appointment comes as Moderna faces the operational challenge of transitioning from pandemic-driven revenue to a diversified portfolio. The company reported FY2025 revenue decline of 39.9 percent against the prior year, with operating margin at negative 158.1 percent. Andres will oversee manufacturing and report to CEO Stéphane Bancel. Jerh Collins, who served as Chief Technical Operations and Quality Officer for four years, is retiring. Collins joined Moderna in October 2022 and helped establish the manufacturing model to support intismeran autogene during his tenure.

What it means

The creation of a dedicated COO role reflects a structural shift at Moderna: the company is moving from a single-product (COVID vaccine) operation toward a multi-program manufacturer. Andres’ prior experience building out Moderna’s global manufacturing network during the pandemic suggests the company expects intismeran autogene to require significant production capacity once it launches. The announcement does not provide a timeline for intismeran autogene’s commercial availability or manufacturing scale targets, leaving open the question of how quickly Moderna expects to ramp production and what capital investment that will require.

The appointment of someone with deep institutional knowledge of Moderna’s operations, rather than an external hire, suggests confidence in the existing manufacturing infrastructure. However, the negative operating margin in FY2025 indicates the company is still burning cash as it pivots away from pandemic revenues. Andres’ mandate to “drive focus, prioritization and execution” across the company hints at potential operational inefficiencies that need addressing as the revenue base shrinks and diversifies.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: Moderna, Inc. and 500+ other names, on the same official data.See the evidence engine →

Collins’ retirement after four years is routine succession planning, though the timing coincides with the company’s shift toward oncology and endemic vaccines. The document does not disclose whether Collins’ departure was planned or prompted by the COO restructuring, nor does it address whether the manufacturing model Collins established for intismeran autogene is complete or still in development.

What to watch

Moderna’s next quarterly earnings report will show whether the company has begun to stabilize revenue decline and whether operating margins are improving as the manufacturing footprint adjusts to endemic vaccine demand. The intismeran autogene regulatory timeline and any manufacturing capacity announcements will clarify whether Andres’ return is preparation for near-term launch or longer-term scaling.

Source: the company’s 8-K filed 2026-09-30 with the SEC.

BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.

For the standing yardsticks on Moderna: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Moderna.

BullScope TerminalYou just read Moderna, Inc.’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Moderna swings to profit as revenue growth accelerates to 29%, raises full-year outlook to 15-25%

by Moe Alsumidaie
November 9, 2026
0

Moderna reported third-quarter revenue of $1.3 billion, up 29% from $1.0 billion a year earlier, and posted net income of $162 million comp

Read moreDetails

Zoetis narrows revenue outlook as U.S. companion animal sales slide, raises profit guidance on margin strength

by Moe Alsumidaie
November 6, 2026
0

Zoetis cut its full-year revenue forecast to $9.220 billion to $9.320 billion, representing organic operational decline of 2 percent to 1 p

Read moreDetails

Viatris Raises 2026 Guidance as Adjusted EBITDA Climbs 9 Percent Year to Date

by Moe Alsumidaie
November 6, 2026
0

Viatris raised the midpoints of its full-year 2026 financial guidance across all key metrics on the strength of nine-month adjusted EBITDA

Read moreDetails

Joby Aviation raises FY26 revenue outlook 15% as eIPP flights and defense contracts accelerate path to certification

by Moe Alsumidaie
November 5, 2026
0

Joby Aviation lifted its full-year 2026 revenue guidance by 15 percent and completed the first crewed eVTOL flights under the federal gover

Read moreDetails

Amgen’s revenue growth slows to 8% as biosimilar competition erodes legacy franchises

by Moe Alsumidaie
November 4, 2026
0

Amgen's third-quarter revenue rose 8% to $10.4 billion, a deceleration from the 10.0% full-year growth rate filed for fiscal 2025. The slow

Read moreDetails
Next Post

Regeneron ties executive pay to pipeline output, not revenue growth, signaling confidence in R&D engine

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

JPMorgan just posted its most profitable quarter ever. The stock is already priced for perfection.

August 25, 2026

Jobs Surge, Prices Linger: The Economy Is Sending Two Messages at Once

September 7, 2026

Trulieve: A $403 Million Loss That Isn’t What It Looks Like, and a Profit That Might Be

September 11, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.